On November 5, 2021 AimedBio reported that its novel brain tumor therapeutics, AMB302, was selected as a government-initiated drug development program by the Korean Drug Development Fund (KDDF).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AMB302 is a first-in-class ADC therapeutics targeting a brain tumor specific fusion oncogene.

AimedBio has confirmed significant tumor killing effect of AMB302 candidate.

AimedBio utilizes patients’ genetic/clinical data and patient-derived samples in the antibody development process, resulting in higher probability of clinical success.

(Press release, AimedBio, NOV 5, 2021, View Source;s_keyword=&s_where=&start=20 [SID1234656924])